Patents by Inventor Casey Maguire

Casey Maguire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene therapy for tuberous sclerosis
    Patent number: 11958887
    Abstract: The invention provides compositions and methods for treating tuberous sclerosis complex (TSC). In particular, provided are condensed tuberins (cTuberins), cTuberin nucleic acids, and recombinant adeno-associated viruses (rAAVs) carrying a cTuberin nucleic acid for treating a patient with TSC.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: April 16, 2024
    Assignee: The General Hospital Corporation
    Inventors: Xandra Breakefield, Casey Maguire, Shilpa Prabhakar, David Yellen
  • Use of Microvesicles in the Treatment of Medical Conditions
    Publication number: 20210040499
    Abstract: Disclosed herein are populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.
    Type: Application
    Filed: June 23, 2020
    Publication date: February 11, 2021
    Applicant: THE GENERAL HOSPITAL CORPORATION d/b/a Massachusetts General Hospital
    Inventors: Johan Karl Olov Skog, Casey Maguire
  • Use of microvesicles in the treatment of medical conditions
    Patent number: 10731179
    Abstract: This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 4, 2020
    Assignee: The General Hospital Corporation
    Inventors: Johan Karl Olov Skog, Casey Maguire
  • Use of microvesicles in the treatment of medical conditions
    Patent number: 10421977
    Abstract: This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: September 24, 2019
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Johan Karl Olov Skog, Casey Maguire
  • Use of Microvesicles in the Treatment of Medical Conditions
    Publication number: 20190264227
    Abstract: This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.
    Type: Application
    Filed: March 20, 2019
    Publication date: August 29, 2019
    Applicant: THE GENERAL HOSPITAL CORPORATION d/b/a Massachusetts General Hospital
    Inventors: Johan Karl Olov Skog, Casey Maguire
  • luciferase variant for high-throughput screening
    Patent number: 8980603
    Abstract: Described herein is a variant of wild type Gaussia luciferase that catalyzes glow-type emission kinetics suited for high-throughput functional screening applications. Polypeptides, functional fragments, variants, and nucleic acids that encode the enhanced luciferase are further described. One such polypeptide corresponds to wild type Gaussia luciferase with a substitution mutation of I for M at position 43 of the mature peptide. Methods of use, assay systems and kits that contain the polypeptides and/or nucleic acids are further described.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: March 17, 2015
    Assignee: The General Hospital Corporation
    Inventors: Bakhos A. Tannous, Casey Maguire
  • GAUSSIA LUCIFERASE VARIANT FOR HIGH-THROUGHPUT SCREENING
    Publication number: 20120122182
    Abstract: Described herein is a variant of wild type Gaussia luciferase that catalyzes glow-type emission kinetics suited for high-throughput functional screening applications. Polypeptides, functional fragments, variants, and nucleic acids that encode the enhanced luciferase are further described. One such polypeptide corresponds to wild type Gaussia luciferase with a substitution mutation of I for M at position 43 of the mature peptide. Methods of use, assay systems and kits that contain the polypeptides and/or nucleic acids are further described.
    Type: Application
    Filed: June 30, 2010
    Publication date: May 17, 2012
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Bakhos A. Tannous, Casey Maguire